Mesothelin-targeting chimeric antigen receptor–modified T cells by transposon system suppress the growth of bile duct carcinoma
Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored. Herein, we developed the second-generation mesothelin-targeting chimeric antigen receptor–modified T cel...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IOS Press
2017-04-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317695949 |